Magnetic resonance-guided focused ultrasounds (MRgFUS) thalamotomy for disabling tremor secondary to multiple sclerosis.
Objective: To describe two patients with disabling tremor secondary to multiple sclerosis (MS) treated with magnetic resonance-guided focused ultrasounds (MRgFUS) thalamotomy. Background: MRgFUS thalamotomy improves…Istradefylline effects on L-Dopa resistant tremor in Parkinson’s disease
Objective: Quantifying Istradefylline(IST) effects in L-Dopa(LD) resistant tremor in Parkinson’s disease(PD) patients. Background: The adenosine A2A receptors control the indirect pathway. Adenosine A2A receptor activation decreases…Assessing the Economic Impact of Transcutaneous Afferent Patterned Stimulation Therapy for Essential Tremor: A Real-World Evidence Study Protocol
Objective: To assess differences in healthcare resource utilization (HCRU) and costs between patients with essential tremor (ET) receiving transcutaneous afferent patterned stimulation (TAPS) therapy and…MR-guided focused ultrasound for essential tremor: exploratory analysis comparing unilateral and staged, bilateral thalamotomy
Objective: This exploratory analysis investigated tremor-motor (TM) outcomes in patients receiving unilateral versus staged, bilateral magnetic resonance-guided focused ultrasound (MRgFUS) VIM thalamotomy for essential tremor…Clinical effectiveness and safety of staged-bilateral MRgFUS for treating essential tremor, a literature review
Objective: To perform a literature overview of the clinical effectiveness and safety of staged-bilateral MR-guided focused ultrasound (MRgFUS) in essential tremor. Background: In the brain,…KINETIC 2: An ongoing phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor
Objective: KINETIC 2 (NCT05173012) is an ongoing, phase 2b, randomized, double-blind, placebo-controlled, dose-response study that aims to evaluate the efficacy, safety, and tolerability of SAGE-324/BIIB124…Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor
Objective: Describe the design of a phase 2 study (NCT05642442) of a once-daily, extended-release formulation of suvecaltamide to treat moderate to severe Parkinson’s disease tremor…Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research
Objective: To understand patient experience in essential tremor (ET), describe meaningful concepts related to treatment benefit, and compare concepts to existing clinical outcome assessments (COAs).…Weighing tremor reduction and side effects: Impact of efficacy and safety outcomes on patient satisfaction at 6 months in MR-guided focused ultrasound thalamotomy for tremor treatment
Objective: To relate efficacy and safety outcomes to patient satisfaction at 6 months after MR-guided focused ultrasound (MRgFUS) thalamotomy in the ventral intermediate nucleus (VIM)…A single centre retrospective study of dual target deep brain stimulation for clinically complex essential and dystonic tremor – a 5-year follow up
Objective: Measure efficacy of dual target deep brain stimulation in pharmaco-refractory tremors. Background: Tremor is characterised by involuntary rhythmic movement present in one or more…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 17
- Next Page »